H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report)’s stock price fell 49.5% during trading on Tuesday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares were traded during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Performance
The stock has a 50 day moving average of $2.02 and a 200 day moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Read More
- Five stocks we like better than H-CYTE
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
